Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

A review indicates that probiotic, prebiotic, and synbiotic supplements could be beneficial for skin health, especially for managing conditions such as eczema.

FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...

Researchers have uncovered a previously unrecognized role for immune cell surface sugars in driving inflammation in psoriasis. Scientists have refined how they understand the role of sugars called ...

Psoriasis is a serious skin disease caused by a weakened immune system. It causes red, scaly patches to form on the skin. It ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

In a surprising new study, scientists from Ewha Woman’s University have found a possible link between common blood pressure ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.

Shares of Takeda Pharmaceuticals rose after the Japanese pharmaceutical major announced positive results from clinical trials of its new treatment for plaque psoriasis. The stock climbed 4.3% in early ...

From white blisters to red and scaly patches, psoriasis skin rashes come in several different forms. How do you know if you have psoriasis or a similar-looking skin condition?

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...